149 related articles for article (PubMed ID: 25814442)
1. Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Bowen JM; White I; Smith L; Tsykin A; Kristaly K; Thompson SK; Karapetis CS; Tan H; Game PA; Irvine T; Hussey DJ; Watson DI; Keefe DM
Support Care Cancer; 2015 Nov; 23(11):3165-72. PubMed ID: 25814442
[TBL] [Abstract][Full Text] [Related]
2. Outcomes from chemoradiotherapy for patients with esophageal cancer.
Pantling AZ; Gossage JA; Mamidanna R; Newman G; Robinson A; Manifold DK; Hale PC
Dis Esophagus; 2011 Apr; 24(3):172-6. PubMed ID: 21073614
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060.
Poplin EA; Jacobson J; Herskovic A; Panella TJ; Valdivieso M; Hutchins LF; Macdonald JS
Cancer; 1996 Nov; 78(9):1851-6. PubMed ID: 8909302
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
[TBL] [Abstract][Full Text] [Related]
5. Concurrent chemoradiotherapy for locally advanced esophageal cancer--a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil.
Hsu CH; Yeh KH; Lui LT; Lee YC; Bu CF; Wang HP; Lin JT; Cheng AL
Anticancer Res; 1999; 19(5C):4463-7. PubMed ID: 10650793
[TBL] [Abstract][Full Text] [Related]
6. Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
Hejna M; Kornek GV; Schratter-Sehn AU; Zach M; Schoder M; Raderer M; Rosen H; Schiessel R; Scheithauer W
Cancer; 1996 Oct; 78(8):1646-50. PubMed ID: 8859175
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Ishida K; Ando N; Yamamoto S; Ide H; Shinoda M
Jpn J Clin Oncol; 2004 Oct; 34(10):615-9. PubMed ID: 15591460
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
10. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Hainsworth JD; Gray JR; Thomas M; Whitworth PL; Davis JL; Greco FA
Cancer J Sci Am; 1999; 5(2):84-91. PubMed ID: 10198730
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
Gaspar LE; Winter K; Kocha WI; Coia LR; Herskovic A; Graham M
Cancer; 2000 Mar; 88(5):988-95. PubMed ID: 10699886
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Lee J; Lee KE; Im YH; Kang WK; Park K; Kim K; Shim YM
Ann Thorac Surg; 2005 Oct; 80(4):1170-5. PubMed ID: 16181835
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
Heath EI; Burtness BA; Heitmiller RF; Salem R; Kleinberg L; Knisely JP; Yang SC; Talamini MA; Kaufman HS; Canto MI; Topazian M; Wu TT; Olukayode K; Forastiere AA
J Clin Oncol; 2000 Feb; 18(4):868-76. PubMed ID: 10673530
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.
Burmeister BH; Walpole ET; Burmeister EA; Thomas J; Thomson DB; Harvey JA; Mark Smithers B; Gotley DC
Int J Clin Oncol; 2005 Aug; 10(4):256-61. PubMed ID: 16136371
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
Roof KS; Coen J; Lynch TJ; Wright C; Fidias P; Willett CG; Choi NC
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1120-8. PubMed ID: 16730135
[TBL] [Abstract][Full Text] [Related]
16. A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
Czito BG; Kelsey CR; Hurwitz HI; Willett CG; Morse MA; Blobe GC; Fernando NH; D'Amico TA; Harpole DH; Honeycutt W; Yu D; Bendell JC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1002-7. PubMed ID: 17197129
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Rodriguez CP; Adelstein DJ; Rice TW; Rybicki LA; Videtic GM; Saxton JP; Murthy SC; Mason DP; Ives DI
J Thorac Oncol; 2010 Feb; 5(2):229-35. PubMed ID: 20009775
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
Maurel J; Cervantes A; Conill C; Salazar R; Martin-Richard M; Pera M; Manzano H; Chirivella I; Gallego R; Marfa X
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):91-6. PubMed ID: 15850907
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
Wright CD; Wain JC; Lynch TJ; Choi NC; Grossbard ML; Carey RW; Moncure AC; Grillo HC; Mathisen DJ
J Thorac Cardiovasc Surg; 1997 Nov; 114(5):811-5; discussion 816. PubMed ID: 9375611
[TBL] [Abstract][Full Text] [Related]
20. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy.
Adelstein DJ; Rice TW; Rybicki LA; Larto MA; Ciezki J; Saxton J; DeCamp M; Vargo JJ; Dumot JA; Zuccaro G
J Clin Oncol; 2000 May; 18(10):2032-9. PubMed ID: 10811667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
